ReviewClinical cancer research : an official journal of the American Association for Cancer Research2011
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.British journal of haematology · 2014Trial
- Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.Medical oncology (Northwood, London, England) · 2014Trial
- The impact of diffuse large B-cell lymphoma-derived exosomes on macrophage polarisation and cytokine release.Archives of medical science : AMS · 2026Article
- B-Cell Lymphoma Following an Indolent Course Over 30 Years with Immunophenotypic Changes at Each Recurrence.European journal of case reports in internal medicine · 2026Article
- Clinical significance of circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large B-cell lymphoma.Clinical and experimental medicine · 2023Article
- Expression and Prognostic Value of Glucose Transporter 3 in Diffuse Large B Cell Lymphoma.OncoTargets and therapy · 2022Article
- Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.Cancers · 2020Article
- Protein-protein interaction modulators: advances, successes and remaining challenges.Biophysical reviews · 2019Review
- Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study.Current medical science · 2019Article
- The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2018Article
- An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.BMC cancer · 2018Article
- MicroRNAs as Biomarkers of B-cell Lymphoma.Biomarker insights · 2018Review
- Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis.Cancer cell international · 2018Article
- Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.BMC cancer · 2017Article
- Article
- Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.PloS one · 2016Article
- Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma (DLBCL). Using this technology, investigators can identify biologic subgroups of DLBCL that provide unique targets for rational therapeutic intervention. This review summarizes these potential targets and updates the progress of clinical development of exciting novel agents for the treatment of DLBCL. Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.